ROCHE HOLDING ADR Aktie

 

SOUTH SAN FRANCISCO (dpa-AFX) - Roche Holding AG (RHHBY) said Monday it has launched AXELIOS 1, a next-generation single-molecule sequencing platform powered by its proprietary sequencing by expan......

Pharma - Die Roche-Titel hinken den Novartis-Aktien hinterher. Gelingt ihnen die Aufholjagd, könnte dies auch im SMI für Rückenwind sorgen – und vielleicht zu einer neuen Bestmarke im Index führen....

Pharma - Roche bringt eine neue Sequenzierungs-Plattform mit dem Namen Axelios 1 auf den Markt....

Basel, 29 June 2026 — Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the launch of AXELIOS 1 based on the innovative SBX technology, with a unique combination of accuracy, speed, flexibility, scalability and cost efficiency that addresses critical bottlenecks in genomics and potentially in clinical research. AXELIOS 1 will enable researchers to make significant discoveries that enhance our understanding of diseases, with the potential to replace existing technologies in pivotal research areas....

Pharma - Die Roche-Titel hinken den Novartis-Aktien hinterher. Gelingt ihnen die Aufholjagd, könnte dies auch im SMI für Rückenwind sorgen – und vielleicht zu einer neuen Bestmarke im Index führen....

Nestlé, Roche und Novartis hieven den SMI auf 14'142 Punkte, während Tech-Werte weiter gemieden werden. Abnehmende Handelsvolumen und geopolitische Risiken könnten die Rallye rasch bremsen....

PA GOODDOCTOR (01833.HK) announced that it recently conducted in-depth exchanges with the China team of Roche. The two parties discussed areas including commercial insurance innovation, full-cycle oncology management, chronic and specialty disease services, and internet healthcare, and finalized multiple key cooperation initiati......

cash-Interview - Wie viel Potenzial in Novartis und Roche steckt und welche Risiken bei Investments zu beachten sind, erklärt Stefan Schneider, Pharma-Analyst bei Vontobel, im cash-Interview....

Im laufenden Jahr dürften so viele Biotechfirmen wie noch nie den Besitzer wechseln. Viele Pharmakonzerne brauchen dringend neue Produkte. Auch Roche und Novartis sind auf Einkaufstour....

Mehdi Hasan goes Head to Head with former Pentagon official David Des Roches on the Iran war....

FDA accepts RHHBY filing for Lunsumio VELO plus Polivy in relapsed or refractory LBCL as a potential chemotherapy-free treatment option....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Die US-Arzneimittelbehörde prüft eine neue Roche-Kombination gegen aggressiven Lymphdrüsenkrebs. Studiendaten zeigen deutliche Vorteile für Patienten....

Pharma - Die Roche-Tochter Genentech erhält Konkurrenz durch ein Generikum....

SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced the FDA has accepted the company's supplemental Biologics License Application for Lunsumio VELO, as a subcutaneous formulatio......

Pharma - Roche hat bei der US-Arzneimittelbehörde FDA einen ergänzenden Zulassungsantrag für die Kombination von Lunsumio Velo und Polivy zur Behandlung von Erwachsenen mit einer aggressiven Form von Lymphdrüsenkrebs eingereicht....

Basel, June 18, 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Lunsumio VELO™ (mosunetuzumab), as a subcutaneous formulation, in combination with Polivy® (polatuzumab vedotin) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL), after at least one prior line of systemic therapy. The FDA is expected to make a decision on approval by 9 February 2027....

Following a Chugai (Roche Group) collaboration with up to $250M in milestones in addition to royalties, and inspired by mammals that defy the rules of aging, Gero uses physics-first AI and human longitudinal data to develop medicines that substantially slow aging and treat age-related diseases.SINGAPORE & SAN FRANCISCO--(BUSINESS WIRE)--#AI--Gero, which previously secured a collaboration with Chugai Pharmaceutical, a member of the Roche Group, including an upfront payment and up to $250M in milestones in addition to royalties, today announced $17M in new financing, bringing total equity funding to $34M. Gero combines longitudinal human data, AI, and a physics-based aging framework for therapeutic target identification and drug design. Gero's approach was born from a crucial but underappreciated observation: nature has already achieved dramatic slowing of aging and extremely long healthy life in several complex mammals. While in humans the risk of death roughly doubles every eight years after early adulth...

SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY) announced that the VENTANA PTEN (SP218) RxDx Assay has become the first immunohistochemistry (IHC) companion diagnostic test to receive approval from ......

Basel, 12 June 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the VENTANAⓇ PTEN (SP218) RxDx Assay is the first immunohistochemistry (IHC) companion diagnostic test to receive U.S. Food and Drug Administration (FDA) approval for determining PTEN protein loss, also known as PTEN deficiency, in tumours of patients with prostate adenocarcinoma. These patients may now be eligible for treatment with AstraZeneca's targeted therapy TRUQAPⓇ (capivasertib)....